PACMAN-AMI Trial

Majeed Alosail presented the PACMAN-AMI Trial which was a double-blind, placebo-controlled, randomized clinical trial comparing the use of biweekly subcutaneous alirocumab to placebo, in addition to high-intensity statin therapy among patients undergoing percutaneous coronary intervention for acute myocardial infarction. Their primary outcome was the change in IVUS-derived percent atheroma volume from baseline to week 52. This trial was published in JAMA earlier this month and was presented at the recent ACC conference.